Dexcom
DXCM · What the business does, what can go wrong, and how options sellers approach it
What it does
DexCom makes continuous glucose monitoring (CGM) systems for people with diabetes. A small sensor worn on the body measures glucose levels through the day and night and sends readings to a phone or a dedicated receiver.
This replaces or reduces the need for fingerstick tests with a traditional blood glucose meter. The data can also feed into compatible insulin pumps and apps that help adjust insulin delivery.
How it makes money
DexCom sells disposable sensors that are replaced regularly, along with reusable transmitters or receivers in some product versions. The sensors are the recurring part of the business, because patients need a fresh supply continuously.
Products reach patients through medical equipment distributors and retail pharmacies. Most of the revenue depends on insurance coverage and reimbursement, so payer decisions matter a great deal.
Why investors own it
- Growth runway: CGM use has been expanding beyond people on intensive insulin therapy to broader groups, including people with Type 2 diabetes.
- Recurring demand: Patients who adopt CGM tend to keep using it, which supports repeat sensor sales.
- Technology position: The company is one of the leading CGM makers and has built integrations with insulin delivery systems.
What can go wrong
- Competition from other CGM makers can pressure pricing and market share.
- Changes in insurance coverage or reimbursement rates can slow adoption or cut margins.
- Medical devices face regulatory scrutiny, and product recalls, quality problems or supply disruptions can damage trust and results.
- Newer therapies for diabetes and obesity could change how many patients need glucose monitoring, though the effect is uncertain.
- The stock can fall sharply on guidance changes, since growth expectations are often high.
What to watch
- Sensor and product revenue growth
- Gross margin trends
- New patient additions, especially in Type 2 and primary care settings
- Insurance coverage and reimbursement decisions
- Regulatory approvals and new product launches
- Competitive launches from rival CGM makers
- Manufacturing capacity and supply reliability
Options income angle
Options on DXCM are generally liquid, with many strikes and expirations, though the busiest trading is usually in near-term contracts close to the current price.
Implied volatility tends to rise ahead of quarterly earnings, competitor news, reimbursement updates and regulatory events. It often falls once results are out.
One caution: this stock has historically moved sharply on earnings and guidance. Selling premium through an earnings report can mean taking on a large gap move that the premium collected may not cover. Covered calls could also cap gains if shares rally strongly.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 12, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Dexcom, a maker of continuous glucose monitors (CGMs, wearable sensors that track blood sugar), reported higher revenue and sharply higher profit for 2025. The filing also flags a Medicare competitive bidding program that is expected to lower CGM reimbursement beginning in 2028, and an open FDA warning letter over its manufacturing quality systems.
How the business did
- Revenue was $4.66 billion, up 16% from 2024. Management attributes the increase mainly to higher sensor volume, with approximately 600,000 - 700,000 net customers added, excluding Stelo customers. Pricing headwinds from greater rebate eligibility and channel mix partly offset this.
- Gross profit was $2.80 billion, up 15%. The gross margin slipped to 60.1% from 60.5%, which management ties to supply-availability inefficiencies, build configurations that lowered production yield, and total replacement costs.
- Operating income was $911.8 million, up 52.0%, and net income was $836.3 million, up 45%. Selling, general and administrative expense included $87.2 million in lower legal expense, mostly from a patent lawsuit settled in December 2024. Other income also included $79.5 million in higher net gains on equity investments.
- Operating cash flow was $1.44 billion, up 46%. Cash and short-term marketable securities ended at $2.00 billion, a decrease of $580.7 million, mainly because the 2025 convertible notes were repaid at maturity in November 2025.
Risks specific to this company
- Medicare pricing: CMS extended competitive bidding to CGMs, with contracting beginning in 2027 and payment changes in 2028. CMS anticipates ten contracts for CGMs, and the filing says Medicare reimbursement for Dexcom's systems is expected to decrease beginning in 2028.
- FDA warning letter: In March 2025, the FDA cited manufacturing and quality-system deficiencies after inspecting the San Diego and Mesa facilities. The letter does not restrict production or sales, but the company cannot say when the FDA will be satisfied, and further action could follow.
- Distributor reliance: Distributor revenue was $3,959.0 million of $4,662.0 million total revenue. Certain distribution agreements each produced 10% or more of total revenue, and a substantial loss of that volume could hurt results.
- Supply and manufacturing: The company depends on single or sole sources for some parts, including the application-specific integrated circuit in the transmitter. Most manufacturing sits in Mesa, Arizona, and Malaysia, and an Ireland plant is still being built.
- Competition: Abbott is the named direct competitor for Stelo and a long-time rival in CGM. The filing also points to GLP-1 weight-loss and diabetes drugs and to a January 6, 2026 FDA guidance that may help wellness wearables.
- Debt: The company has $1.25 billion of 0.375% convertible senior notes due 2028 and a $200.0 million credit facility that expires in 2026. It had no outstanding borrowings under the credit facility at year end.
What management is watching
- Product development focused on improved performance, convenience and intelligent insulin delivery, along with partnerships with insulin pump makers and consumer technology companies.
- New opportunities including people with pre-diabetes, obesity, pregnancy and hospital use.
- Significant capital spending over the next year on equipment and manufacturing facilities, including Ireland and Malaysia.
- Capital return through the 2025 Share Repurchase Program, authorized up to $750.0 million, of which $500.0 million had been used by year end.
- The measures management calls most important: revenue, gross profit, operating income, net income and operating cash flow. It also notes that the first quarter is seasonally lower than the fourth quarter.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Dexcom's third quarter showed strong operating growth: revenue rose 11% and operating income rose 35%. Net income fell 3% because the prior-year quarter included a large investment gain and this quarter had less interest income. Operating cash flow for the quarter was down 51%, and the company completed its 2026 share repurchase program during the quarter.
How the business did
- Quarter: Revenue was $1.34 billion, gross profit was $864.4 million (64% of revenue versus 60% a year earlier), and operating income was $327.2 million. Net income was $275.1 million. Diluted earnings per share were $0.72 versus $0.70.
- Drivers and segments: The company attributed the revenue growth mainly to higher sales volume of disposable sensors as its customer base grew. U.S. revenue was $969.8 million versus $851.9 million, and International was $374.7 million versus $357.4 million. Better margins came from sales volume, G7 15 Day benefits and manufacturing efficiencies, partly offset by inventory reserve charges tied to the planned end of G6 manufacturing. Selling, general and administrative expense rose, including $20.7 million in added advertising and marketing.
- Why net income lagged: Other income, net was $7.5 million versus $109.8 million. The prior year had an $82.5 million gain on equity investments, and interest and dividend income was $18.4 million lower.
- Year to date: Nine-month revenue was $3,844.8 million, operating income was $900.8 million, and net income was $723.7 million, up 27%. Operating cash flow was $1,120.4 million versus $1,146.7 million. The filing cites the timing of payables and higher inventory as reasons for the drop in working capital cash flow.
- Capital return: Cash used to repurchase common stock rose by $816.4 million for the nine months. Cash, cash equivalents and short-term marketable securities were $1.82 billion, with no borrowings under the credit facility.
What management is watching
- The company expects significant capital expenditures over the next year as it invests in equipment and manufacturing facilities. It believes cash and credit access cover its needs for at least the next 12 months.
- Management expects to allocate at least 50% of cash generated from operations, net of planned capital expenditures, to share repurchases over the course of its long-range plan.
- The senior convertible notes (debt that can be exchanged for cash or shares if certain conditions are met) mature in May 2028 and could be converted earlier.
- The company says it tracks revenue, gross profit, operating income, net income and operating cash flow as its most important indicators. In June 2026, Stelo, its over-the-counter glucose biosensor, received FDA clearance for children ages 2 years and older who do not use insulin.
New or changed risks
- In October 2026, the Board authorized a 2027 Share Repurchase Program of up to $1.00 billion, with repurchases ending no later than December 31, 2027.
- The program does not obligate the company to buy any amount of stock. It may be extended, modified, suspended or discontinued at any time.
- The filing says the buybacks could affect the stock price and raise its volatility. It also says there is no assurance they will help the stock price or earnings per share.
- Factors that could lead the company to cut back or stop repurchases include unfavorable market conditions, other investment or strategic opportunities, and the availability of funds.
Follow DXCM in Kortex
The Kortex app shows DXCM's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.